BioNTech SE Sponsored ADR $BNTX Stock Holdings Lowered by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lessened its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 70.4% in the third quarter, Holdings Channel reports. The firm owned 11,843 shares of the company’s stock after selling 28,124 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in BioNTech were worth $1,164,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Flossbach Von Storch SE bought a new position in BioNTech in the 2nd quarter valued at about $207,142,000. Bank of America Corp DE raised its position in shares of BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after buying an additional 166,432 shares in the last quarter. First Trust Advisors LP raised its position in shares of BioNTech by 116.0% in the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after buying an additional 451,124 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of BioNTech by 79.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock worth $74,774,000 after acquiring an additional 337,412 shares during the period. Finally, SEB Asset Management AB bought a new stake in shares of BioNTech during the 1st quarter worth approximately $17,804,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BNTX. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. UBS Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Canaccord Genuity Group cut their target price on BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Finally, Berenberg Bank set a $140.00 target price on BioNTech in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average target price of $125.80.

BioNTech Stock Performance

BioNTech stock opened at $86.86 on Tuesday. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $98.36 and its two-hundred day moving average price is $97.44. The stock has a market cap of $21.97 billion, a PE ratio of -11.09 and a beta of 1.25.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%. The firm’s revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.60) EPS. As a group, analysts expect that BioNTech SE Sponsored ADR will post -6.62 earnings per share for the current fiscal year.

Insider Buying and Selling at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of BioNTech stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 807,209 shares of company stock valued at $79,246,837. Company insiders own 19.20% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.